Platelet activation in Alzheimer disease

Archives of Neurology

Volumn 55, Issue 4, 1998, Pages 530-536

  Sevush, Steven ^a   Jy, Wenche ^a   Horstman, Lawrence L ^a   Mao, Wei Wei ^a   Kolodny, Luciano ^a   Ahn, Yeon S ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PADGEM PROTEIN;

ALZHEIMER DISEASE; ARTICLE; DISEASE ASSOCIATION; DISEASE SEVERITY; FEMALE; FIBRINOGEN BLOOD LEVEL; FLOW CYTOMETRY; HUMAN; MAJOR CLINICAL STUDY; MALE; PATHOGENESIS; PRIORITY JOURNAL; SEX DIFFERENCE; THROMBOCYTE ACTIVATION; THROMBOCYTE AGGREGATION; THROMBOCYTE COUNT;

AGED; ALZHEIMER DISEASE; CASE-CONTROL STUDIES; FEMALE; FIBRINOGEN; FLOW CYTOMETRY; HUMANS; MALE; MIDDLE AGED; PLATELET ACTIVATION; PLATELET COUNT; PLATELET FACTOR 3;

EID: 0031895587     PISSN: 00039942     EISSN: None     Source Type: Journal    
DOI: 10.1001/archneur.55.4.530     Document Type: Article

References (48)

1. Blass JP, Gibson GE. Nonneurol markers in Alzheimer's disease. Alzheimer Dis Assoc Disord. 1993;6:205-224.
2. Zubenko GS, Malinakova I, Chojnacki B. Proliferation of internal membranes in platelets from patients with Alzheimer's disease. J Neuropathol Exp Neurol. 1987; 46:407-418.
3. Piletz JE, Sarasua M, Whitehouse P, Chotani M. Intracellular membranes are more fluid in platelets of Alzheimer's disease patients. Neurobiol Aging. 1991;12:401-406.
4. 2 adrenoreceptors in platelets. J Am Geriatr Soc. 1989;37:741-744.
5. Adolfsson R, Gottfries CG, Oreland L, Wiberg A, Winblad B. Increased activity of brain and platelet monamine oxidase in dementia of Alzheimer type. Life Sci. 1980; 27:1029-1034.
6. Smith RC, Beng TH, Kralik P, Vroulis G, Gordon J, Wolff J. Platelet monoamine oxidase in Alzheimer's disease. J Gerontol. 1982;37:572-574.
7. Parker WD, Mahr NJ, Filley CM, et al. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology. 1994;44:1086-1090.
8. Matsushima H, Shimohama S, Tanaka S, et al. Platelet protein kinase C levels in Alzheimer's disease. Neurobiol Aging. 1994;15:681-684.
9. Matsushima H, Shimohama S, Fujimoto S, Takenawa T, Kimura J. Reduction of platelet phospholipase C activity in patients with Alzheimer disease. Alzheimer Dis Assoc Disord. 1995;9:213-217.
10. Bush AI, Martins RN, Rumble B, et al. The amyloid precursor protein of Alzheimer's disease is released by human platelets. J Biol Chem. 1990;265:15977-15983.
11. Chen M, Inestrosa NC, Ross GS, Fernandez HL. Platelets are the primary source of amyloid β-peptide in human blood. Biochem Biophys Res Commun. 1995; 213:96-103.
12. 14C]5-hydroxytryptamine. Neurosci Lett. 1993;163:8-10.
13. Koren P, Diver-Haber A, Adunsky A, Rabinowitz M, Hershkowitz M. Uptake of serotonin into platelets of senile dementia of the Alzheimer type patients. Biol Sci. 1993;48:B93-B96.
14. Kumar AM, Kumar M, Sevush S, Ruiz J, Eisdorfer C. Serotonin uptake and its kinetics in platelets of women with Alzheimer's disease. Psychiatr Res. 1995; 59:145-150.
15. Kumar AM, Sevush S, Kumar M, Ruiz J, Eisdorter C. Peripheral serotonin in Alzheimer's disease. Neuropsychobiology. 1995;32:9-12.
16. Rosenberg RN, Baskin F, Fosmire JA, et al. Altered amyloid protein processing in platelets of patients with Alzheimer disease. Arch Neurol. 1997;54:139-144.
17. Larsen E, Celi A, Gilbert GE, et al. PADGEM protein: a receptor that mediates the interaction of activated platelets with neutrophils and monocytes. Cell. 1989;59: 305-312.
18. Sims PJ, Wiedmer T, Esmon CT, Weiss HJ, Shattil SJ. Assembly of the platelet prothrombinase complex is linked to vesiculation of the platelet plasma membrane. J Biol Chem. 1989;264:17049-17057.
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan E. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology. 1984;34:939-944.
20. McGeer PL, Schulzer M, McGeer EG. Arthritis and anti-inflammatory agents as possible protective factors for Alzheimer's disease: a review of 17 epidemiologic studies. Neurology. 1996;47:425-432.
21. Lee YJ, Wenche J, Horstman LL, et al. Elevated platelet microparticles in transient ischemic attacks, lacunar infarcts, and multiinfarct dementias. Thromb Res. 1993;72:295-304.
22. Horstman LL, Jy W, Schultz DR, Mao WW, Ahn YS. Complement-mediated fragmentation and lysis of opsonized platelets: gender differences in sensitivity. J Lab Clin Med. 1994;123:515-525.
23. Jy W, Horstman LL, Wang F, Duncan RC, Ahn YS. Platelet factor 3 in plasma fractions: its relation to microparticle size and thromboses. Thromb Res. 1995; 80:471-482.
24. Folstein MF, Folstein SF, McGugh PR. Mini-Mental State Exam: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975; 12:189-198.
25. Sevush S, Guterman A, Villalon AV. Improved verbal learning after outpatient physostigmine therapy in patients with dementia of the Alzheimer's type. J Clin Psychiatry. 1991;52:300-303.
26. Sevush S, Leve N, Brickman A. Age at onset and pattern of cognitive impairment in probable Alzheimer's disease. J Neuropsychiatr Clin Neurosci. 1993;5:66-72.
27. Blessed G, Tomlinson BE, Roth M. The association between quantitative measures of dementia and senile change in the cerebral grey matter of elderly subjects. Br J Psychiatry. 1968;114:797-811.
28. Duara R, Alberola-Lopez RF, Barker WW, et al. A comparison of familial and sporadic Alzheimer's disease. Neurology. 1993;43:1377-1384.
29. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in dementia. Biol Psychiatry. 1988;23:271-284.
30. Cohen-Mansfield J. Agitated behaviors in the elderly, II: preliminary results in the cognitively deteriorated. J Am Geriatr Soc. 1986;34:722-727.
31. SAS/STAT User's Guide: Release 6.03 Edition. Cary, NC: SAS Institute Inc; 1988.
32. Stern Y, Gurland B, Tatemichi TK, Tang MX, Wilder D, Mayeux R. Influence of education and occupation on the incidence of Alzheimer's disease. JAMA. 1994; 271:1004-1010.
33. Graves AB, van Kuijn CM, Chandra V, et al. Alcohol and tobacco consumption as risk factors for Alzheimer's disease: a collaborative re-analysis of case-control studies. Int J Epidemiol. 1991;20(suppl 2):S48-S57.
34. The Canadian Study of Health and Aging. Risk factors for Alzheimer's disease in Canada. Neurology. 1994;44:2072-2080.
35. Malyszko J, Urano T, Knofler R, et al. Daily variations of platelet aggregation in relation to blood and plasma serotonin in diabetes. Thromb Res. 1994;75:569-576.
36. DeMet EM, Chicz-DeMet A. Seasonal patterns in platelet ligand binding are related to membrane proteins. Biol Psychiatry. 1996;39:430-435.
37. Dandona P, Thusu K, Khurana U, Love J, Aljada A, Mousa S. Calcium, calmodulin and protein kinase C dependence of platelet shape change. Thromb Res. 1996; 81:163-175.
38. Mari D, Parnetti L, Coppola R, et al. Hemostasis abnormalities in patients with vascular dementia and Alzheimer's disease. Thromb Haemost. 1996;75:216-218.
39. Rinder HM, Bonan JL, Rinder CS, Ault KA, Smith BR. Dynamics of leukocyteplatelet adhesion in whole blood. Blood. 1991;78:1730-1737.
40. van Nostrand WE, Schmaier AH, Farrow JS, Cunningham DD. Protease nexin-II (amyloid β-protein precursor): a platelet α-granule protein. Science. 1990;248: 745-748.
41. Nomura S, Suzuki M, Katsura K, et al. Platelet-derived microparticles may influence the development of atherosclerosis in diabetes mellitus. Atherosclerosis. 1995;116:235-240.
42. Fukatsu R, Tsuzuki K, Takamanu Y, et al. Is APP in cultured cells and platelets processed in multiple pathways? Soc Neurosci. 1996;22:190. Abstract.
43. Scheuner D, Eckman C, Jensen M, et al. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. Nature Med. 1996;2:864-870.
44. Tokuda T, Fukushima T, Ikeda S, et al. Plasma levels of amyloid β proteins Ab1-40 and Ab1-42(43) are elevated in Down's syndrome. Ann Neurol. 1997;41:271-273.
45. Vinters HV. Cerebral amyloid angiopathy: a critical review. Stroke. 1987;18:311-324.
46. Selkoe DJ. Molecular pathology of amyloidogenic protein and the role of vascular amyloidosis in Alzheimer's disease. Neurobiol Aging. 1989;10:387-395.
47. Tagliavini F, Ghiso J, Timmers WF, Giaccone G, Bugiani O, Frangione B. Coexistence of Alzheimer's amyloid precursor protein and amyloid protein in cerebral vessel walls. Lab Invest. 1990;62:761-767.
48. Podlisny MB, Mammen AL, Schlossmacher MG, Palmert MR, Younkin SG, Selkoe DJ. Detection of soluble forms of the β-amyloid precursor protein in human plasma. Biochem Biophys Res Commun. 1990;167:1094-1101.